Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson , Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson , Rina Hui , Tibor Csőszi , Andrea Fülöp , Maya Gottfried , Nir Peled , Ali Tafreshi , Sinéad Cuffe , Mary O’Brien , Suman Rao , Katsuyuki Hotta , Melanie A. Leiby , Gregory M. Lubiniecki , Yue Shentu , Reshma Rangwala , Julie R. Brahmer
2016 New England Journal of Medicine 9,645 citations

Abstract

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy. (Funded by Merck; KEYNOTE-024 ClinicalTrials.gov number, NCT02142738 .).

Keywords

PembrolizumabMedicineLung cancerInternal medicineHazard ratioOncologyChemotherapyCancerGastroenterologyConfidence intervalImmunotherapy

Affiliated Institutions

Related Publications

Publication Info

Year
2016
Type
article
Volume
375
Issue
19
Pages
1823-1833
Citations
9645
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

9645
OpenAlex

Cite This

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. (2016). Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine , 375 (19) , 1823-1833. https://doi.org/10.1056/nejmoa1606774

Identifiers

DOI
10.1056/nejmoa1606774